SCHEMBL2548384

SCHEMBL2548384

O=C1NC(=O)C(=Cc2ccc(F)cc2OC(F)(F)F)S1

nearest known ligand 0.58

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PIM1 P11309 5/20 0.58
PIM2 Q9P1W9 5/20 0.58
PTPN1 P18031 9/20 0.56
SCN9A Q15858 1/20 0.56
KMT2A Q03164 3/20 0.53
LMNA P02545 1/20 0.53
HPGD P15428 1/20 0.53
NR1H4 Q96RI1 1/20 0.51
IGF1R P08069 1/20 0.50
MEN1 O00255 2/20 0.48
ALDH1A1 P00352 2/20 0.48
TTR P02766 2/20 0.48
KDM4E B2RXH2 1/20 0.48
BLM P54132 1/20 0.48
PLA2G1B P04054 1/20 0.48
POLB P06746 1/20 0.48
HTT P42858 1/20 0.48
ATG4B Q9Y4P1 1/20 0.48
CISD1 Q9NZ45 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2548382 1.00 PIM1 (0.58) PIM1PIM2PTPN1SCN9AKMT2A
SCHEMBL2546672 0.90 PTPN1 (0.65) PIM1PIM2PTPN1SCN9AKMT2A
SCHEMBL2546668 0.90 PTPN1 (0.65) PIM1PIM2PTPN1SCN9AKMT2A
SCHEMBL2545582 0.87 PIM1 (0.69) PIM1PIM2PTPN1SCN9AKMT2A
SCHEMBL2545580 0.87 PIM1 (0.69) PIM1PIM2PTPN1SCN9AKMT2A
SCHEMBL1248939 0.85 SCN9A (0.62) PIM1PIM2SCN9AKMT2ALMNA
SCHEMBL1248941 0.85 SCN9A (0.62) PIM1PIM2SCN9AKMT2ALMNA
SCHEMBL12891880 0.85 SCN9A (0.62) PIM1PIM2SCN9AKMT2ALMNA
SCHEMBL2543481 0.82 SCN9A (0.58) PIM1PIM2PTPN1SCN9AKMT2A
SCHEMBL2543483 0.82 SCN9A (0.58) PIM1PIM2PTPN1SCN9AKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110263664-A1 Inhibitors of PIM-1 Protein Kinases, Compositions and Methods for Treating Prostate Cancer MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) 2011-10-27 US claimed
EP-2217235-A2 INHIBITORS OF PIM PROTEIN KINASES, COMPOSITIONS, AND METHODS FOR TREATING CANCER Musc Foundation for Research Development (US) 2010-08-18 EP claimed
WO-2009064486-A9 INHIBITORS OF PIM PROTEIN KINASES, COMPOSITIONS, AND METHODS FOR TREATING CANCER MUSC FOUND FOR RES DEV (US) 2009-07-16 WO claimed
WO-2009064486-A2 INHIBITORS OF PIM PROTEIN KINASES, COMPOSITIONS, AND METHODS FOR TREATING CANCER MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) 2009-05-22 WO claimed
US-20110263664-A1 Inhibitors of PIM-1 Protein Kinases, Compositions and Methods for Treating Prostate Cancer MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) 2011-10-27 US disclosed
EP-2217235-A2 INHIBITORS OF PIM PROTEIN KINASES, COMPOSITIONS, AND METHODS FOR TREATING CANCER Musc Foundation for Research Development (US) 2010-08-18 EP disclosed
WO-2009064486-A9 INHIBITORS OF PIM PROTEIN KINASES, COMPOSITIONS, AND METHODS FOR TREATING CANCER MUSC FOUND FOR RES DEV (US) 2009-07-16 WO disclosed
WO-2009064486-A2 INHIBITORS OF PIM PROTEIN KINASES, COMPOSITIONS, AND METHODS FOR TREATING CANCER MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) 2009-05-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110263664-A1 Inhibitors of PIM-1 Protein Kinases, Compositions and Methods for Treating Prostate Cancer PIM1, PIM2, PIM3 PIM1 1/4885PIM2 2/4885PTPN1 1133/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.